ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells 1,000 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Jeanne Thoma sold 1,000 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $71.53, for a total transaction of $71,530.00. Following the sale, the director directly owned 26,762 shares of the company’s stock, valued at $1,914,285.86. This represents a 3.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ ANIP traded up $0.21 during midday trading on Monday, reaching $70.40. The stock had a trading volume of 357,649 shares, compared to its average volume of 331,768. The company’s 50 day moving average price is $76.97 and its 200 day moving average price is $78.17. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. ANI Pharmaceuticals, Inc. has a twelve month low of $69.58 and a twelve month high of $99.39. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of 15.17 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals’s quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ANIP. Canaccord Genuity Group dropped their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research note on Monday, August 10th. Weiss Ratings downgraded ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Guggenheim lowered their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Finally, Leerink Partners started coverage on ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.57.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Tidal Investments LLC bought a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $248,000. WINTON GROUP Ltd purchased a new stake in ANI Pharmaceuticals during the second quarter valued at about $4,558,000. Corient Private Wealth LP raised its holdings in shares of ANI Pharmaceuticals by 95.2% during the 2nd quarter. Corient Private Wealth LP now owns 24,106 shares of the specialty pharmaceutical company’s stock valued at $1,995,000 after buying an additional 11,754 shares in the last quarter. Amundi raised its holdings in shares of ANI Pharmaceuticals by 595.5% during the 2nd quarter. Amundi now owns 31,793 shares of the specialty pharmaceutical company’s stock valued at $2,632,000 after buying an additional 27,222 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in ANI Pharmaceuticals in the 2nd quarter worth approximately $1,449,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.